Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards to 23 new non-executive employees under its 2025 Inducement Plan.
The awards were granted on November 1 and November 14, 2026, and included options to buy 842 common shares at $430.36 per share and 8,296 time-based restricted stock units. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4).
Positive
- Minor pointHiring incentives were a material factor in 23 new non-executive employees accepting employment.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.8,296 time-based restricted stock units could dilute existing shareholders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Options to buy 842 common shares at $430.36 per share could dilute existing shareholders if exercised.
News Explained
Vesting is conditional on continued employment: options vest
Key Figures
- Employees receiving awards
- 23 employees
- New non-executive employees
- Stock options
- 842 shares
- Granted in aggregate
- Restricted stock units
- 8,296 units
- Granted in aggregate
- Option exercise price
- $430.36 per share
- Equal to the closing price on the grant date
- Initial option vesting
- 25%
- Vests on the first anniversary of the grant date
- Subsequent option vesting
- 6.25%
- Vests on each quarterly anniversary after the first anniversary
- Restricted stock unit vesting
- Four equal installments
- On each of the first through fourth anniversaries of the grant date
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2026 and November 14, 2026 to a total of 23 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 842 shares of Madrigal’s common stock, and in the aggregate 8,296 time-based restricted stock units. All options were granted on November 1, 2026 and have an exercise price of
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.